Replies to post #23445 on CytoSorbents Corporation (CTSO)

[Greenaccountingbean]

CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
CytoSorb is now distributed in a total of 65 countries throughout the world

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation)
NEWS PROVIDED BY
CytoSorbents Corporation
Jun 24, 2020, 07:30 ET
MONMOUTH JUNCTION, N.J., June 24, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the commercial launch and immediate availability of CytoSorb in nine Latin American countries including Colombia, Argentina, Perú, Guatemala, Ecuador, Bolivia, the Dominican Republic, El Salvador, and Costa Rica. CytoSorb has been available in Panamá and Chile for many years, has recently received marketing approval in Mexico with initial sales, and is pending final registration in Brazil. CytoSorb is now distributed in a total of 65 countries worldwide. This expansion is particularly timely as Central and South American countries have become "intense zones" for COVID-19 transmission, according to the World Health Organization. In Latin American countries where CytoSorb is distributed, 2.1 million cases of COVID-19 have been reported to date, out of a total population of approximately 562 million, or approximately 0.4%, and a mortality rate of 4.6%. This compares to 2.4 million cases in the U.S. out of a total population of 331 million, or approximately 0.7%, and a mortality rate of 5.1%. Experts predict that COVID-19 will not stop until significant herd immunity develops with 60-70% of the world population either infected or vaccinated, suggesting the global pandemic is still in its early stages.

In Panamá, CytoSorb has been sold commercially for over three years in a wide range of applications. CytoSorb has been used to treat many critically-ill COVID-19 patients, and is specifically included in the Panamá COVID-19 treatment guidelines. Dr. Nicolás Hurtado, Nephrologist and Intensivist from the National Hospital of Panamá in Panamá City, stated, "We have had 12 critical patients with COVID-19 on CytoSorb therapy and most of them responded positively. CytoSorb is a weapon we regularly use on our patients when we see the cytokine storm approaching."

Mr. Carlos Giron, General Manager of Servicios Quirúrgicos Guatemala, commented, "We are proud to be the exclusive distributor of CytoSorb® in Guatemala, the largest country in Central America. Our passion is to help healthcare professionals save lives every day and strongly believe that CytoSorb will play an important role in treating a wide variety of life-threatening conditions by fighting cytokine storm and hyper-inflammation. At this precise moment, the need is to treat sepsis in patients with COVID-19, where the numbers of new cases and deaths have been rising rapidly. With CytoSorb now immediately available, our team is excited to begin selling the therapy through the official commercial launch and promotion of CytoSorb in the country through digital media and in person with demos, webinars, and scientific literature and case studies, among others."

Mr. Carlos Florez, General Manager of Fresenius Medical Care Colombia, exclusive distributor for CytoSorb in the Intensive Care segment, stated, "In Colombia's intensive care units, hyper-inflammatory pathologies associated mainly with sepsis - such as septic shock, acute respiratory distress syndrome (ARDS), and acute kidney injury (AKI) - and trauma, are on the rise. This not only leads to increased mortality, but also negatively impacts health system economics because of the high cost of therapies and resources dedicated to save the lives of these patients. These diseases often require a multi-systemic approach and we are very optimistic that CytoSorb therapy can adjunctively help to address these conditions and decrease both ICU stay and mortality. In particular, in critically-ill COVID-19 patients with multi-organ failure, CytoSorb provides physicians with a new treatment option to help those suffering from cytokine storm."

Dr. Christian Steiner, MD, Senior Vice President of Sales and Marketing at CytoSorbents stated, "We are proud and excited to work with such a strong network of professional partners. We believe this is essential to a successful commercial launch in Central and South America, where we have big plans. With our partners, we are also thankful that this expansion comes just in time to potentially help patients in the ongoing COVID-19 pandemic. As a leading treatment of cytokine storm across the world, CytoSorb is now immediately available in these countries to help treat complications such as respiratory failure, shock and other organ failure, with the goal of reducing fatal outcomes. These complications are often triggered by cytokine storm and are common to a wide variety of illnesses, including COVID-19."